Fig 6 shows the serum levels of major inflammatory markers, including IL-1β, IL-6, TNF-α, and CRP, across the control, T2DM, semaglutide-treated, and dapagliflozin-treated groups. This evidence concerns the gene CRP and type 2 diabetes mellitus.